S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.80 (-5.00%)
BABA   68.47 (-0.60%)
T   16.31 (-0.12%)
F   12.05 (-0.08%)
MU   106.85 (-4.54%)
GE   147.29 (-3.69%)
CGC   7.93 (+1.28%)
DIS   111.61 (-0.73%)
AMC   3.20 (+9.59%)
PFE   25.77 (+1.50%)
PYPL   61.87 (-0.37%)
XOM   119.58 (+0.89%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.80 (-5.00%)
BABA   68.47 (-0.60%)
T   16.31 (-0.12%)
F   12.05 (-0.08%)
MU   106.85 (-4.54%)
GE   147.29 (-3.69%)
CGC   7.93 (+1.28%)
DIS   111.61 (-0.73%)
AMC   3.20 (+9.59%)
PFE   25.77 (+1.50%)
PYPL   61.87 (-0.37%)
XOM   119.58 (+0.89%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.80 (-5.00%)
BABA   68.47 (-0.60%)
T   16.31 (-0.12%)
F   12.05 (-0.08%)
MU   106.85 (-4.54%)
GE   147.29 (-3.69%)
CGC   7.93 (+1.28%)
DIS   111.61 (-0.73%)
AMC   3.20 (+9.59%)
PFE   25.77 (+1.50%)
PYPL   61.87 (-0.37%)
XOM   119.58 (+0.89%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.80 (-5.00%)
BABA   68.47 (-0.60%)
T   16.31 (-0.12%)
F   12.05 (-0.08%)
MU   106.85 (-4.54%)
GE   147.29 (-3.69%)
CGC   7.93 (+1.28%)
DIS   111.61 (-0.73%)
AMC   3.20 (+9.59%)
PFE   25.77 (+1.50%)
PYPL   61.87 (-0.37%)
XOM   119.58 (+0.89%)
Free Trial
NASDAQ:ELYM

Eliem Therapeutics (ELYM) Stock Price, News & Analysis

→ With the “Bitcoin Loophole” you can supercharge the gains by 10x or more (From DTI) (Ad)
Free ELYM Stock Alerts
$4.09
-0.09 (-2.15%)
(As of 12:34 PM ET)
Compare
Today's Range
$4.03
▼
$4.44
50-Day Range
$2.54
▼
$4.75
52-Week Range
$2.34
▼
$5.19
Volume
114,620 shs
Average Volume
584,810 shs
Market Capitalization
$113.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media
ELYM stock logo

About Eliem Therapeutics Stock (NASDAQ:ELYM)

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

ELYM Stock Price History

ELYM Stock News Headlines

April 15, 2024 | prnewswire.com
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm
April 12, 2024 | finanznachrichten.de
Eliem Therapeutics, Inc.: Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
April 19, 2024 | Insiders Exposed (Ad)
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
April 11, 2024 | stockhouse.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN
April 11, 2024 | finance.yahoo.com
Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal
April 11, 2024 | msn.com
Enlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare movers
April 11, 2024 | markets.businessinsider.com
Eliem Therapeutics To Buy Tenet Medicines, Plans $120 Mln Private Placement; Stock Up In Pre-market
April 11, 2024 | businesswire.com
ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders
April 19, 2024 | Insiders Exposed (Ad)
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
April 11, 2024 | globenewswire.com
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
April 5, 2024 | msn.com
ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023
March 6, 2024 | finance.yahoo.com
Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
November 19, 2023 | morningstar.com
Checkpoint Therapeutics Inc CKPT
November 15, 2023 | morningstar.com
Eliem Therapeutics Inc ELYM
September 28, 2023 | finance.yahoo.com
Eliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth Plans
July 21, 2023 | finance.yahoo.com
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
July 21, 2023 | msn.com
Eliem Therapeutics’ stock soars 21% premarket after company says it may sell itself
July 20, 2023 | benzinga.com
What's Happening With Eliem Therapeutics Shares Today?
July 20, 2023 | finanznachrichten.de
Eliem Therapeutics, Inc.: Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
July 20, 2023 | marketwatch.com
Eliem Therapeutics Shares Rally Premarket on Exploration of Options >ELYM
July 20, 2023 | markets.businessinsider.com
Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?
July 20, 2023 | finance.yahoo.com
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
June 7, 2023 | markets.businessinsider.com
Stifel Nicolaus Sticks to Its Buy Rating for Eliem Therapeutics (ELYM)
May 25, 2023 | markets.businessinsider.com
Stifel Nicolaus Reaffirms Their Buy Rating on Eliem Therapeutics (ELYM)
May 12, 2023 | finanznachrichten.de
Eliem Therapeutics, Inc.: Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
May 11, 2023 | seekingalpha.com
Eliem Therapeutics GAAP EPS of -$0.84
May 11, 2023 | finance.yahoo.com
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
See More Headlines
Receive ELYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
4/19/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ELYM
CUSIP
N/A
CIK
1768446
Web
www.eliemtx.com
Phone
877-354-3689
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,120,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-31.45%
Return on Assets
-30.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
38.92
Quick Ratio
38.92

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.90 per share
Price / Book
1.07

Miscellaneous

Outstanding Shares
27,720,000
Free Float
26,416,000
Market Cap
$115.87 million
Optionable
Not Optionable
Beta
0.51
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Andrew Levin M.D. (Age 46)
    Ph.D., Principal Financial Officer & Executive Chairman
    Comp: $73k
  • Dr. Valerie Morisset Ph.D. (Age 54)
    Chief Scientific Officer and Executive VP of Research & Development
    Comp: $617.87k
  • Ms. Emily Pimblett (Age 40)
    Principal Accounting Officer
  • Ms. Jo Palmer-Phillips Ph.D.
    Chief Development Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ELYM Stock Analysis - Frequently Asked Questions

How have ELYM shares performed in 2024?

Eliem Therapeutics' stock was trading at $2.70 on January 1st, 2024. Since then, ELYM stock has increased by 53.0% and is now trading at $4.13.
View the best growth stocks for 2024 here.

When is Eliem Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ELYM earnings forecast.

How were Eliem Therapeutics' earnings last quarter?

Eliem Therapeutics, Inc. (NASDAQ:ELYM) released its quarterly earnings data on Monday, November, 8th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.19.

When did Eliem Therapeutics IPO?

Eliem Therapeutics (ELYM) raised $75 million in an initial public offering (IPO) on Tuesday, August 10th 2021. The company issued 6,000,000 shares at a price of $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO.

How do I buy shares of Eliem Therapeutics?

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELYM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith